DE102005015128B4 - Wafer enthaltend Steroidhormone - Google Patents
Wafer enthaltend Steroidhormone Download PDFInfo
- Publication number
- DE102005015128B4 DE102005015128B4 DE102005015128A DE102005015128A DE102005015128B4 DE 102005015128 B4 DE102005015128 B4 DE 102005015128B4 DE 102005015128 A DE102005015128 A DE 102005015128A DE 102005015128 A DE102005015128 A DE 102005015128A DE 102005015128 B4 DE102005015128 B4 DE 102005015128B4
- Authority
- DE
- Germany
- Prior art keywords
- steroid hormone
- application system
- carrier material
- film
- steroid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003270 steroid hormone Substances 0.000 title claims abstract description 62
- 235000012431 wafers Nutrition 0.000 title description 45
- 239000012876 carrier material Substances 0.000 claims abstract description 19
- 229920002678 cellulose Polymers 0.000 claims abstract description 11
- 239000001913 cellulose Substances 0.000 claims abstract description 11
- 108010010803 Gelatin Proteins 0.000 claims abstract description 5
- 229920000881 Modified starch Polymers 0.000 claims abstract description 5
- 229920001577 copolymer Polymers 0.000 claims abstract description 5
- 229920000159 gelatin Polymers 0.000 claims abstract description 5
- 239000008273 gelatin Substances 0.000 claims abstract description 5
- 235000019322 gelatine Nutrition 0.000 claims abstract description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 5
- 235000019426 modified starch Nutrition 0.000 claims abstract description 5
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims abstract description 5
- 229920002472 Starch Polymers 0.000 claims abstract description 4
- 235000019698 starch Nutrition 0.000 claims abstract description 4
- 239000008107 starch Substances 0.000 claims abstract description 4
- YSGQGNQWBLYHPE-CFUSNLFHSA-N (7r,8r,9s,10r,13s,14s,17s)-17-hydroxy-7,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 YSGQGNQWBLYHPE-CFUSNLFHSA-N 0.000 claims description 27
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 21
- 229960003604 testosterone Drugs 0.000 claims description 13
- 239000003098 androgen Substances 0.000 claims description 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 12
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 12
- 210000000214 mouth Anatomy 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 235000010980 cellulose Nutrition 0.000 claims description 9
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 8
- 229960004719 nandrolone Drugs 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003246 corticosteroid Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 230000003232 mucoadhesive effect Effects 0.000 claims description 5
- 206010002261 Androgen deficiency Diseases 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 4
- -1 deflazacortalcohol Chemical compound 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 229940011871 estrogen Drugs 0.000 claims description 4
- 239000000262 estrogen Substances 0.000 claims description 4
- 229960003973 fluocortolone Drugs 0.000 claims description 4
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 229960003387 progesterone Drugs 0.000 claims description 4
- 239000000186 progesterone Substances 0.000 claims description 4
- 230000033764 rhythmic process Effects 0.000 claims description 4
- 230000002060 circadian Effects 0.000 claims description 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 claims description 2
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 claims description 2
- 229960003473 androstanolone Drugs 0.000 claims description 2
- 229960005471 androstenedione Drugs 0.000 claims description 2
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 claims description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims description 2
- 229960000978 cyproterone acetate Drugs 0.000 claims description 2
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims description 2
- 229960001145 deflazacort Drugs 0.000 claims description 2
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 claims description 2
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 claims description 2
- 229960003309 dienogest Drugs 0.000 claims description 2
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 229960004845 drospirenone Drugs 0.000 claims description 2
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 claims description 2
- 229960002568 ethinylestradiol Drugs 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- XZBJVIQXJHGUBE-HZMVJJPJSA-N fluocortolone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]2(C)C[C@@H]1O XZBJVIQXJHGUBE-HZMVJJPJSA-N 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims description 2
- 229960005352 gestodene Drugs 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229960004400 levonorgestrel Drugs 0.000 claims description 2
- UXYRZJKIQKRJCF-TZPFWLJSSA-N mesterolone Chemical compound C1C[C@@H]2[C@@]3(C)[C@@H](C)CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C UXYRZJKIQKRJCF-TZPFWLJSSA-N 0.000 claims description 2
- 229960005272 mesterolone Drugs 0.000 claims description 2
- 229960003578 metenolone Drugs 0.000 claims description 2
- ANJQEDFWRSLVBR-VHUDCFPWSA-N methenolone Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C ANJQEDFWRSLVBR-VHUDCFPWSA-N 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 229960002037 methylprednisolone aceponate Drugs 0.000 claims description 2
- DALKLAYLIPSCQL-YPYQNWSCSA-N methylprednisolone aceponate Chemical compound C1([C@@H](C)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]2(C)C[C@@H]1O DALKLAYLIPSCQL-YPYQNWSCSA-N 0.000 claims description 2
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 claims description 2
- 229960000464 oxandrolone Drugs 0.000 claims description 2
- 239000003961 penetration enhancing agent Substances 0.000 claims description 2
- 229960005205 prednisolone Drugs 0.000 claims description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 230000001548 androgenic effect Effects 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 description 20
- 238000010521 absorption reaction Methods 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 210000004400 mucous membrane Anatomy 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 210000005178 buccal mucosa Anatomy 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- 229940030486 androgens Drugs 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 150000003431 steroids Chemical group 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000000541 pulsatile effect Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 150000003839 salts Chemical group 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 2
- 239000005844 Thymol Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 238000000451 chemical ionisation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000027288 circadian rhythm Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960000790 thymol Drugs 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002807 Thiomer Polymers 0.000 description 1
- 229960001413 acetanilide Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 229940094957 androgens and estrogen Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 238000012894 bi-exponential function Methods 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000001047 desmosome Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000012052 hydrophilic carrier Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 150000003145 progesterone derivatives Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (30)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005015128A DE102005015128B4 (de) | 2005-03-31 | 2005-03-31 | Wafer enthaltend Steroidhormone |
| TW095108474A TWI393576B (zh) | 2005-03-31 | 2006-03-13 | 供雄激素透黏膜投予用的呈膜形式之黏膜黏著性藥學組成物 |
| CNA2006800071551A CN101132766A (zh) | 2005-03-31 | 2006-03-15 | 含有类固醇激素的片剂 |
| UAA200712054A UA92011C2 (ru) | 2005-03-31 | 2006-03-15 | Облатка, содержащая стероидные гормоны |
| BRPI0609601-8A BRPI0609601A2 (pt) | 2005-03-31 | 2006-03-15 | sistema de aplicação em forma de filme para a administração transmucosal de um hormÈnio esteróide, processo para a produção e uso de um hormÈnio esteróide |
| PCT/EP2006/002358 WO2006102990A2 (de) | 2005-03-31 | 2006-03-15 | Wafer enthaltend steroidhormone |
| EA200702102A EA014183B1 (ru) | 2005-03-31 | 2006-03-15 | Пленочная аппликационная система для трансмукозного введения стероидного гормона |
| CN201510393577.8A CN104983669B (zh) | 2005-03-31 | 2006-03-15 | 含有类固醇激素的片剂 |
| MX2007012081A MX2007012081A (es) | 2005-03-31 | 2006-03-15 | Tableta que contiene hormonas esteroides. |
| KR1020147008056A KR20140063740A (ko) | 2005-03-31 | 2006-03-15 | 스테로이드 호르몬을 함유하는 정제 |
| NZ592882A NZ592882A (en) | 2005-03-31 | 2006-03-15 | Mucoadhesive film comprising testosterone and cellulose derivatives |
| KR1020077022368A KR101428625B1 (ko) | 2005-03-31 | 2006-03-15 | 스테로이드 호르몬을 함유하는 정제 |
| EP06723435.1A EP1863444B1 (de) | 2005-03-31 | 2006-03-15 | Wafer enthaltend steroidhormone |
| JP2008503397A JP5843416B2 (ja) | 2005-03-31 | 2006-03-15 | ステロイドホルモンを含むタブレット |
| AU2006228820A AU2006228820B2 (en) | 2005-03-31 | 2006-03-15 | Tablet containing steroid hormones |
| CA2598892A CA2598892C (en) | 2005-03-31 | 2006-03-15 | Tablet containing steroid hormones |
| SG2012016937A SG179459A1 (en) | 2005-03-31 | 2006-03-15 | Tablet containing steroid hormones |
| SV2006002466A SV2008002466A (es) | 2005-03-31 | 2006-03-27 | Oblea que contiene hormonas esteroides ref. p-sv-79.953/gh |
| DO2006000070A DOP2006000070A (es) | 2005-03-31 | 2006-03-27 | Oblea que contiene hormonas esteroides |
| UY29441A UY29441A1 (es) | 2005-03-31 | 2006-03-27 | Oblea que contiene hormonas esteroides |
| GT200600126A GT200600126A (es) | 2005-03-31 | 2006-03-27 | Oblea que contiene hormonas estoides |
| PE2006000341A PE20061194A1 (es) | 2005-03-31 | 2006-03-27 | Oblea que contiene hormonas esteroides |
| US11/391,646 US9763960B2 (en) | 2005-03-31 | 2006-03-28 | Wafer comprising steroid hormones |
| AR20060101273A AR054245A1 (es) | 2005-03-31 | 2006-03-31 | Oblea que contiene hormonas esteroides |
| ZA200706116A ZA200706116B (en) | 2005-03-31 | 2007-07-24 | Tablet containing steroid hormones |
| IL186081A IL186081A0 (en) | 2005-03-31 | 2007-09-19 | Tablet containing steroid hormones |
| CR9468A CR9468A (es) | 2005-03-31 | 2007-10-23 | Oblea que contiene hormonas esteroides |
| NO20075404A NO20075404L (no) | 2005-03-31 | 2007-10-24 | Tablett inneholdende steroidhormoner |
| JP2013087238A JP2013155190A (ja) | 2005-03-31 | 2013-04-18 | ステロイドホルモンを含むタブレット |
| US15/684,245 US20170348321A1 (en) | 2005-03-31 | 2017-08-23 | Wafer Comprising Steroid Hormones |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005015128A DE102005015128B4 (de) | 2005-03-31 | 2005-03-31 | Wafer enthaltend Steroidhormone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE102005015128A1 DE102005015128A1 (de) | 2006-10-05 |
| DE102005015128B4 true DE102005015128B4 (de) | 2008-12-11 |
Family
ID=36998911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE102005015128A Expired - Fee Related DE102005015128B4 (de) | 2005-03-31 | 2005-03-31 | Wafer enthaltend Steroidhormone |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9763960B2 (enExample) |
| EP (1) | EP1863444B1 (enExample) |
| JP (2) | JP5843416B2 (enExample) |
| KR (2) | KR20140063740A (enExample) |
| CN (2) | CN104983669B (enExample) |
| AR (1) | AR054245A1 (enExample) |
| AU (1) | AU2006228820B2 (enExample) |
| BR (1) | BRPI0609601A2 (enExample) |
| CA (1) | CA2598892C (enExample) |
| CR (1) | CR9468A (enExample) |
| DE (1) | DE102005015128B4 (enExample) |
| DO (1) | DOP2006000070A (enExample) |
| EA (1) | EA014183B1 (enExample) |
| GT (1) | GT200600126A (enExample) |
| IL (1) | IL186081A0 (enExample) |
| MX (1) | MX2007012081A (enExample) |
| NO (1) | NO20075404L (enExample) |
| NZ (1) | NZ592882A (enExample) |
| PE (1) | PE20061194A1 (enExample) |
| SG (1) | SG179459A1 (enExample) |
| SV (1) | SV2008002466A (enExample) |
| TW (1) | TWI393576B (enExample) |
| UA (1) | UA92011C2 (enExample) |
| UY (1) | UY29441A1 (enExample) |
| WO (1) | WO2006102990A2 (enExample) |
| ZA (1) | ZA200706116B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
| US8241664B2 (en) | 2005-04-15 | 2012-08-14 | Clarus Therapeutics, Inc | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
| DE102006027796A1 (de) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Estrogen-Gestagen-Kombinationen |
| NZ586666A (en) * | 2008-02-13 | 2012-04-27 | Bayer Schering Pharma Ag | Estradiol-containing drug delivery system |
| KR20100117603A (ko) * | 2008-02-13 | 2010-11-03 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 안정화 효과를 갖는 약물 전달 시스템 |
| TW201008569A (en) * | 2008-08-08 | 2010-03-01 | Bayer Schering Pharma Ag | Progestin-containing drug delivery system |
| CA2744127A1 (en) * | 2008-11-21 | 2010-05-27 | Bayer Schering Pharma Aktiengesellschaft | Drug delivery system |
| US12186426B2 (en) | 2009-10-30 | 2025-01-07 | Ix Biopharma Ltd. | Solid dosage form |
| EP2493457B1 (en) | 2009-10-30 | 2017-08-09 | IX Biopharma Ltd | Fast dissolving solid dosage form |
| US10806703B2 (en) * | 2012-01-20 | 2020-10-20 | Lts Lohmann Therapie-System Ag | Transmucosal administration system for a pharmaceutical drug |
| AU2012385956B2 (en) | 2012-07-23 | 2017-03-30 | Crayola, Llc | Dissolvable films and methods of using the same |
| DE102017112527B4 (de) * | 2017-06-07 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | Schnell zerfallende Schaumwafer mit hohem Flächengewicht |
| MX2020008147A (es) * | 2018-02-02 | 2020-10-28 | Acerus Biopharma Inc | Metodos de terapia de testosterona. |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB981372A (en) * | 1960-05-04 | 1965-01-27 | Pfizer Ltd | Pharmaceutical formulations for oral administration to animals |
| DE19646392A1 (de) * | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
| US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| WO2002003965A1 (en) * | 2000-07-06 | 2002-01-17 | Delsys Pharmaceutical Corporation | Method for formulating healthcare products with enhanced stability |
| WO2005011618A2 (en) * | 2003-07-31 | 2005-02-10 | Ivax Corporation | Methods for the treatment of male and female sexual dysfunction |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4136162A (en) | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
| US4764378A (en) * | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
| DE69312487T2 (de) * | 1992-05-18 | 1997-11-27 | Minnesota Mining & Mfg | Einrichtung zur transmucosalen wirkstoffabgabe |
| DE19847252B4 (de) * | 1998-10-02 | 2004-02-12 | Jenapharm Gmbh & Co. Kg | Bukkal applizierbare bioadhäsive Systeme mit zeitlich gesteuerter Wirkstofffreisetzung enthaltend Testosteronester und fakultativ zusätzlich Testosteron |
| US6552024B1 (en) * | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| US20030092658A1 (en) * | 2001-02-02 | 2003-05-15 | Meyers Rachel E. | Novel human enzyme family members and uses thereof |
| GB0100760D0 (en) * | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
| US6585997B2 (en) * | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| FR2832311B1 (fr) * | 2001-11-21 | 2004-04-16 | Besins Int Belgique | Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations |
| JO2492B1 (en) * | 2003-04-28 | 2009-10-05 | شيرينج ايه جي | A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients |
| PL1670433T3 (pl) * | 2003-10-10 | 2013-03-29 | Ferring Bv | Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze |
-
2005
- 2005-03-31 DE DE102005015128A patent/DE102005015128B4/de not_active Expired - Fee Related
-
2006
- 2006-03-13 TW TW095108474A patent/TWI393576B/zh not_active IP Right Cessation
- 2006-03-15 EA EA200702102A patent/EA014183B1/ru not_active IP Right Cessation
- 2006-03-15 UA UAA200712054A patent/UA92011C2/ru unknown
- 2006-03-15 BR BRPI0609601-8A patent/BRPI0609601A2/pt not_active Application Discontinuation
- 2006-03-15 AU AU2006228820A patent/AU2006228820B2/en not_active Ceased
- 2006-03-15 KR KR1020147008056A patent/KR20140063740A/ko not_active Ceased
- 2006-03-15 CN CN201510393577.8A patent/CN104983669B/zh active Active
- 2006-03-15 KR KR1020077022368A patent/KR101428625B1/ko not_active Expired - Fee Related
- 2006-03-15 WO PCT/EP2006/002358 patent/WO2006102990A2/de not_active Ceased
- 2006-03-15 JP JP2008503397A patent/JP5843416B2/ja not_active Expired - Fee Related
- 2006-03-15 NZ NZ592882A patent/NZ592882A/xx not_active IP Right Cessation
- 2006-03-15 CN CNA2006800071551A patent/CN101132766A/zh active Pending
- 2006-03-15 SG SG2012016937A patent/SG179459A1/en unknown
- 2006-03-15 CA CA2598892A patent/CA2598892C/en active Active
- 2006-03-15 MX MX2007012081A patent/MX2007012081A/es active IP Right Grant
- 2006-03-15 EP EP06723435.1A patent/EP1863444B1/de active Active
- 2006-03-27 SV SV2006002466A patent/SV2008002466A/es not_active Application Discontinuation
- 2006-03-27 DO DO2006000070A patent/DOP2006000070A/es unknown
- 2006-03-27 UY UY29441A patent/UY29441A1/es not_active Application Discontinuation
- 2006-03-27 PE PE2006000341A patent/PE20061194A1/es not_active Application Discontinuation
- 2006-03-27 GT GT200600126A patent/GT200600126A/es unknown
- 2006-03-28 US US11/391,646 patent/US9763960B2/en not_active Expired - Fee Related
- 2006-03-31 AR AR20060101273A patent/AR054245A1/es not_active Application Discontinuation
-
2007
- 2007-07-24 ZA ZA200706116A patent/ZA200706116B/xx unknown
- 2007-09-19 IL IL186081A patent/IL186081A0/en unknown
- 2007-10-23 CR CR9468A patent/CR9468A/es unknown
- 2007-10-24 NO NO20075404A patent/NO20075404L/no not_active Application Discontinuation
-
2013
- 2013-04-18 JP JP2013087238A patent/JP2013155190A/ja active Pending
-
2017
- 2017-08-23 US US15/684,245 patent/US20170348321A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB981372A (en) * | 1960-05-04 | 1965-01-27 | Pfizer Ltd | Pharmaceutical formulations for oral administration to animals |
| DE19646392A1 (de) * | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
| US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| WO2002003965A1 (en) * | 2000-07-06 | 2002-01-17 | Delsys Pharmaceutical Corporation | Method for formulating healthcare products with enhanced stability |
| WO2005011618A2 (en) * | 2003-07-31 | 2005-02-10 | Ivax Corporation | Methods for the treatment of male and female sexual dysfunction |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69604600T2 (de) | Neue Zuckerbeschichtungszusammensetzung zum Auftragen auf komprimierte Wirkstofftabletten | |
| DE602004011374T2 (de) | Transdermale pharmazeutische zusammensetzung | |
| DE102005015128B4 (de) | Wafer enthaltend Steroidhormone | |
| DE60127134T2 (de) | Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel | |
| EP1509201B1 (de) | Wirkstoffhaltige filmförmige zubereitungen mit verbesserter chemischer stabilität, und verfahren zu deren herstellung | |
| EP1978927A1 (de) | Filmförmige arzneiformen zur anwendung in der mundhöhle (wafer) | |
| WO1999001109A2 (de) | Transdermales therapeutisches system (tts) zur verabreichung von levonorgestrel | |
| EP3908253A1 (de) | Oraler dünnfilm | |
| DE102006027794A1 (de) | Antihypertonie-Kombinationswafer | |
| DE102004023984A1 (de) | Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol | |
| DE4342842A1 (de) | Polymeres, bio-erodierbares Abgabesystem für die periodontale Tasche | |
| WO2004052347A1 (de) | Transmucosale und transdermale arzneimittel mit verbesserter wirkstoffresorption | |
| WO2007098828A1 (de) | Kontrazeptivum | |
| WO2007085420A1 (de) | Arzneimittel umfassend eine hormonkombination | |
| DE69819503T2 (de) | Verwendung eines 7-alpha-methyl-17-alpha-ethinyl-östran-derivats zur behandlung von arteriosklerose | |
| EP1848406A2 (de) | Feste perorale arzneiform zur kontrazeption, die dienogest und ethinylestradiol enthält | |
| DE102006027796A1 (de) | Estrogen-Gestagen-Kombinationen | |
| EP2674150A1 (de) | Pharmazeutische Zubereitung mit verbesserter Stabilität des Wirkstoffs | |
| HK1116055A (en) | Tablet containing steroid hormones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8127 | New person/name/address of the applicant |
Owner name: BAYER SCHERING PHARMA AG, 13353 BERLIN, DE Owner name: TAISEI KAKO CO., LTD., OSAKA, JP |
|
| 8127 | New person/name/address of the applicant |
Owner name: TAISEI KAKO CO., LTD., OSAKA, JP Owner name: BAYER SCHERING PHARMA AKIENGESELLSCHAFT, 13353, DE |
|
| 8127 | New person/name/address of the applicant |
Owner name: LTS LOHMANN THERAPIE-SYSTEME AG, 56626 ANDERNA, DE Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 1335, DE |
|
| 8364 | No opposition during term of opposition | ||
| R081 | Change of applicant/patentee |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE Free format text: FORMER OWNERS: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 13353 BERLIN, DE; LTS LOHMANN THERAPIE-SYSTEME AG, 56626 ANDERNACH, DE Effective date: 20120613 Owner name: LTS LOHMANN THERAPIE-SYSTEME AG, DE Free format text: FORMER OWNERS: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 13353 BERLIN, DE; LTS LOHMANN THERAPIE-SYSTEME AG, 56626 ANDERNACH, DE Effective date: 20120613 Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE Free format text: FORMER OWNER: BAYER SCHERING PHARMA AKTIENGES, LTS LOHMANN THERAPIE-SYSTEME AG, , DE Effective date: 20120613 Owner name: LTS LOHMANN THERAPIE-SYSTEME AG, DE Free format text: FORMER OWNER: BAYER SCHERING PHARMA AKTIENGES, LTS LOHMANN THERAPIE-SYSTEME AG, , DE Effective date: 20120613 |
|
| R081 | Change of applicant/patentee |
Owner name: LTS LOHMANN THERAPIE-SYSTEME AG, DE Free format text: FORMER OWNERS: BAYER PHARMA AKTIENGESELLSCHAFT, 13353 BERLIN, DE; LTS LOHMANN THERAPIE-SYSTEME AG, 56626 ANDERNACH, DE Effective date: 20130626 Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE Free format text: FORMER OWNERS: BAYER PHARMA AKTIENGESELLSCHAFT, 13353 BERLIN, DE; LTS LOHMANN THERAPIE-SYSTEME AG, 56626 ANDERNACH, DE Effective date: 20130626 Owner name: LTS LOHMANN THERAPIE-SYSTEME AG, DE Free format text: FORMER OWNER: BAYER PHARMA AKTIENGESELLSCHAFT, LTS LOHMANN THERAPIE-SYSTEME AG, , DE Effective date: 20130626 Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE Free format text: FORMER OWNER: BAYER PHARMA AKTIENGESELLSCHAFT, LTS LOHMANN THERAPIE-SYSTEME AG, , DE Effective date: 20130626 |
|
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |